Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Identifieur interne : 000306 ( Main/Corpus ); précédent : 000305; suivant : 000307Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
Auteurs : Steven R. Schwid ; Janice Bausch ; David Oakes ; Lynn Schuchter ; Caroline Tanner ; Misser Forrest ; Anthony E. Lang ; Ira ShoulsonSource :
- Movement Disorders [ 0885-3185 ] ; 2010-09-15.
English descriptors
- KwdEn :
Abstract
We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.23006
Links to Exploration step
ISTEX:289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DFLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Bausch, Janice" sort="Bausch, Janice" uniqKey="Bausch J" first="Janice" last="Bausch">Janice Bausch</name><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Schuchter, Lynn" sort="Schuchter, Lynn" uniqKey="Schuchter L" first="Lynn" last="Schuchter">Lynn Schuchter</name><affiliation><mods:affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation><mods:affiliation>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</mods:affiliation></affiliation></author><author><name sortKey="Forrest, Misser" sort="Forrest, Misser" uniqKey="Forrest M" first="Misser" last="Forrest">Misser Forrest</name><affiliation><mods:affiliation>H. Lundbeck A/S, Copenhagen, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23006</idno><idno type="url">https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000306</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><author><name sortKey="Schwid, Steven R" sort="Schwid, Steven R" uniqKey="Schwid S" first="Steven R." last="Schwid">Steven R. Schwid</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Bausch, Janice" sort="Bausch, Janice" uniqKey="Bausch J" first="Janice" last="Bausch">Janice Bausch</name><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation><mods:affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Schuchter, Lynn" sort="Schuchter, Lynn" uniqKey="Schuchter L" first="Lynn" last="Schuchter">Lynn Schuchter</name><affiliation><mods:affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline" sort="Tanner, Caroline" uniqKey="Tanner C" first="Caroline" last="Tanner">Caroline Tanner</name><affiliation><mods:affiliation>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</mods:affiliation></affiliation></author><author><name sortKey="Forrest, Misser" sort="Forrest, Misser" uniqKey="Forrest M" first="Misser" last="Forrest">Misser Forrest</name><affiliation><mods:affiliation>H. Lundbeck A/S, Copenhagen, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation><mods:affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</mods:affiliation></affiliation></author><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15">2010-09-15</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1801">1801</biblScope><biblScope unit="page" to="1808">1808</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</idno><idno type="DOI">10.1002/mds.23006</idno><idno type="ArticleID">MDS23006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>L‐dopa</term><term>Melanoma</term><term>Parkinson's disease</term><term>apoptosis</term><term>cancer</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Steven R. Schwid MD</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Janice Bausch BS</name><affiliations><json:string>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>David Oakes PhD</name><affiliations><json:string>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</json:string></affiliations></json:item><json:item><name>Lynn Schuchter MD</name><affiliations><json:string>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</json:string></affiliations></json:item><json:item><name>Caroline Tanner MD</name><affiliations><json:string>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</json:string></affiliations></json:item><json:item><name>Misser Forrest MD</name><affiliations><json:string>H. Lundbeck A/S, Copenhagen, Denmark</json:string></affiliations></json:item><json:item><name>Anthony E. Lang MD</name><affiliations><json:string>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</json:string></affiliations></json:item><json:item><name>Ira Shoulson MD</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Melanoma</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cancer</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>L‐dopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>apoptosis</value></json:item></subject><articleId><json:string>MDS23006</json:string></articleId><language><json:string>eng</json:string></language><abstract>We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>6.954</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1474</abstractCharCount><pdfWordCount>4374</pdfWordCount><pdfCharCount>31402</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>215</abstractWordCount></qualityIndicators><title>Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><corporate><json:item><name>the PSG PRECEPT Investigators</name></json:item></corporate><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>1808</last><first>1801</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.23006</json:string></doi><id>289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: Nothing to report.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title><author><orgName>the PSG PRECEPT Investigators</orgName></author><author><persName><forename type="first">Steven R.</forename><surname>Schwid</surname></persName><roleName type="degree">MD</roleName><note type="biography">Deceased.</note><affiliation>Deceased.</affiliation><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Janice</forename><surname>Bausch</surname></persName><roleName type="degree">BS</roleName><affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">David</forename><surname>Oakes</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</affiliation></author><author><persName><forename type="first">Lynn</forename><surname>Schuchter</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation></author><author><persName><forename type="first">Caroline</forename><surname>Tanner</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</affiliation></author><author><persName><forename type="first">Misser</forename><surname>Forrest</surname></persName><roleName type="degree">MD</roleName><affiliation>H. Lundbeck A/S, Copenhagen, Denmark</affiliation></author><author><persName><forename type="first">Anthony E.</forename><surname>Lang</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Toronto Western Hospital, Movement Disorders Centre, 399 Bathurst Street, MC 7‐402, Toronto, Ontario, Canada M5T 2S8</p></note><affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</affiliation></author><author><persName><forename type="first">Ira</forename><surname>Shoulson</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1801">1801</biblScope><biblScope unit="page" to="1808">1808</biblScope></imprint></monogr><idno type="istex">289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</idno><idno type="DOI">10.1002/mds.23006</idno><idno type="ArticleID">MDS23006</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Melanoma</term></item><item><term>cancer</term></item><item><term>L‐dopa</term></item><item><term>Parkinson's disease</term></item><item><term>apoptosis</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-07-21">Received</change><change when="2009-12-29">Registration</change><change when="2010-09-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v25:12</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2010-09-15">15 September 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="50" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.23006</doi><idGroup><id type="unit" value="MDS23006"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-07-21"></event><event type="manuscriptRevised" date="2009-11-23"></event><event type="manuscriptAccepted" date="2009-12-29"></event><event type="firstOnline" date="2010-07-28"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-07-28"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="publishedOnlineFinalForm" date="2010-09-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1801</numbering><numbering type="pageLast">1808</numbering></numberingGroup><correspondenceTo>Toronto Western Hospital, Movement Disorders Centre, 399 Bathurst Street, MC 7‐402, Toronto, Ontario, Canada M5T 2S8</correspondenceTo><objectNameGroup><objectName elementName="appendix">APPENDIX</objectName></objectNameGroup><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS23006.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="22"></count><count type="wordTotal" number="5422"></count></countGroup><titleGroup><title type="main" xml:lang="en">Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease<link href="#fn7"></link></title><title type="short" xml:lang="en">Cancer Incidence in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" noteRef="#fn8"><personName><givenNames>Steven R.</givenNames><familyName>Schwid</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Janice</givenNames><familyName>Bausch</familyName><degrees>BS</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>David</givenNames><familyName>Oakes</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Lynn</givenNames><familyName>Schuchter</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Caroline</givenNames><familyName>Tanner</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af5"><personName><givenNames>Misser</givenNames><familyName>Forrest</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af6" corresponding="yes"><personName><givenNames>Anthony E.</givenNames><familyName>Lang</familyName><degrees>MD</degrees></personName><contactDetails><email>lang@uhnres.utoronto.ca</email></contactDetails></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Ira</givenNames><familyName>Shoulson</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au9" creatorRole="author"><groupName>the PSG PRECEPT Investigators</groupName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</unparsedAffiliation></affiliation><affiliation xml:id="af5" countryCode="DK" type="organization"><unparsedAffiliation>H. Lundbeck A/S, Copenhagen, Denmark</unparsedAffiliation></affiliation><affiliation xml:id="af6" countryCode="CA" type="organization"><unparsedAffiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Melanoma</keyword><keyword xml:id="kwd2">cancer</keyword><keyword xml:id="kwd3">L‐dopa</keyword><keyword xml:id="kwd4">Parkinson's disease</keyword><keyword xml:id="kwd5">apoptosis</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all <i>P</i> > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn7"><p>Potential conflict of interest: Nothing to report.</p></note><note xml:id="fn8"><p>Deceased.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cancer Incidence in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Steven R.</namePart><namePart type="family">Schwid</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><description>Deceased.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Janice</namePart><namePart type="family">Bausch</namePart><namePart type="termsOfAddress">BS</namePart><affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">David</namePart><namePart type="family">Oakes</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Biostatistics and Computational Biology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lynn</namePart><namePart type="family">Schuchter</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline</namePart><namePart type="family">Tanner</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Clinical Research, Parkinson's Institute, Sunnyvale, California</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Misser</namePart><namePart type="family">Forrest</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>H. Lundbeck A/S, Copenhagen, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony E.</namePart><namePart type="family">Lang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Neurology, Toronto Western Hospital, Toronto, Ontario</affiliation><description>Correspondence: Toronto Western Hospital, Movement Disorders Centre, 399 Bathurst Street, MC 7‐402, Toronto, Ontario, Canada M5T 2S8</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ira</namePart><namePart type="family">Shoulson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>the PSG PRECEPT Investigators</namePart><description>Department of Neurology, University of Rochester, Rochester, New YorkDepartment of Biostatistics and Computational Biology, University of Rochester, Rochester, New YorkDepartment of Medicine, University of Pennsylvania, Philadelphia, PennsylvaniaDepartment of Clinical Research, Parkinson's Institute, Sunnyvale, CaliforniaH. Lundbeck A/S, Copenhagen, DenmarkDivision of Neurology, Toronto Western Hospital, Toronto, Ontario</description></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-09-15</dateIssued><dateCaptured encoding="w3cdtf">2008-07-21</dateCaptured><dateValid encoding="w3cdtf">2009-12-29</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">22</extent><extent unit="words">5422</extent></physicalDescription><abstract lang="en">We performed a placebo‐controlled trial of CEP‐1347, an inhibitor of neuronal apoptotic cell death, in patients with early Parkinson's disease (PD) to determine whether long‐term therapy would slow disability progression. This also provided an opportunity to monitor cancer incidence in a large cohort of PD patients followed prospectively including periods before and after patients developed disability requiring dopaminergic therapy. This was a multicenter study of 806 patients with early PD, without disability requiring dopaminergic therapy, assigned randomly to placebo or one of three doses of CEP‐1347. Patients were monitored for an average of 1.8 years (1,467 patient‐years) with routine cancer screening evaluations and annual skin examinations by a dermatologist. There was no significant excess of cancers among patients taking CEP‐1347 compared with placebo for any cancer type (all P > 0.1). Nonmelanoma skin cancers were the most common cancer type observed. The incidence of melanomas was 20.9 times that predicted in the general population. Most melanomas occurred in patients who had never taken dopaminergic therapy. We found no evidence that CEP‐1347 affected cancer incidence within 2 years of follow‐up. Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: Nothing to report.</note><subject lang="en"><genre>Keywords</genre><topic>Melanoma</topic><topic>cancer</topic><topic>L‐dopa</topic><topic>Parkinson's disease</topic><topic>apoptosis</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1801</start><end>1808</end><total>8</total></extent></part></relatedItem><identifier type="istex">289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF</identifier><identifier type="DOI">10.1002/mds.23006</identifier><identifier type="ArticleID">MDS23006</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000306 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000306 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:289579D6291DDAC2C3C9AC8DCCE80355F5CCA1DF
|texte= Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |